4/25
08:25 am
cvac
CureVac (NASDAQ: CVAC) was downgraded by analysts at SVB Leerink LLC from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $12.00.
Neutral
Report
CureVac (NASDAQ: CVAC) was downgraded by analysts at SVB Leerink LLC from an "outperform" rating to a "market perform" rating. They now have a $4.00 price target on the stock, down previously from $12.00.
4/24
07:40 am
cvac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update [Yahoo! Finance]
Low
Report
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update [Yahoo! Finance]
4/24
07:33 am
cvac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer [Yahoo! Finance]
Low
Report
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer [Yahoo! Finance]
4/24
07:33 am
cvac
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK [Yahoo! Finance]
Low
Report
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK [Yahoo! Finance]
4/24
07:30 am
cvac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Low
Report
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
4/24
07:20 am
cvac
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Low
Report
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4/24
07:20 am
cvac
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Low
Report
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4/23
11:31 am
cvac
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30% [Yahoo! Finance]
Low
Report
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30% [Yahoo! Finance]
4/18
07:15 am
cvac
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
High
Report
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
4/16
07:33 am
cvac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines [Yahoo! Finance]
Low
Report
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines [Yahoo! Finance]
4/16
07:15 am
cvac
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Low
Report
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4/5
10:25 am
cvac
CureVac (NASDAQ: CVAC) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Low
Report
CureVac (NASDAQ: CVAC) had its "neutral" rating re-affirmed by analysts at Guggenheim.
4/4
07:28 am
cvac
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK [Yahoo! Finance]
Low
Report
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK [Yahoo! Finance]
4/4
07:15 am
cvac
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Low
Report
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
2/22
06:47 am
cvac
Global Advanced Therapy Medicinal Products CDMO Market Analysis Report 2024-2030: : Increasing Investment and Clinical Trial Expenditure Driving Demand, Oncology Dominance and Emerging Treatment Areas [Yahoo! Finance]
Low
Report
Global Advanced Therapy Medicinal Products CDMO Market Analysis Report 2024-2030: : Increasing Investment and Clinical Trial Expenditure Driving Demand, Oncology Dominance and Emerging Treatment Areas [Yahoo! Finance]
2/5
05:00 am
cvac
Allergy Immunotherapy Soars: Anticipating a $2.69 Billion Market by 2028 with an Impressive CAGR of 8.12% [Yahoo! Finance]
Low
Report
Allergy Immunotherapy Soars: Anticipating a $2.69 Billion Market by 2028 with an Impressive CAGR of 8.12% [Yahoo! Finance]